Regulatory science for generic dry powder inhalers (DPIs) in the United States (US) has
evolved over the last decade. In 2013, the US Food and Drug Administration (FDA) …

Regulatory science for generic dry powder inhalation products worldwide has evolved over
the last decade. The revised draft guidance Metered Dose Inhaler (MDI) and Dry Powder …

Dry powder inhalers (DPIs) are drug–device combination products where the complexity of
the formulation, its interaction with the device, and input from users play important roles in …

In Japan, the development of generic oral dry powder inhaler (DPI) drug products for
marketing approval has recently increased. The Pharmaceuticals and Medical Devices …

Dry powder inhalers (DPIs) are used to deliver locally acting drugs (eg, bronchodilators and
corticosteroids) for treatment of lung diseases such as asthma and chronic obstructive …

In this review, an extensive analysis of dry powder inhalers (DPIs) is offered, focusing on
their characteristics, formulation, stability, and manufacturing. The advantages of pulmonary …

During the last decades, the term “drug delivery systems”(DDSs) has almost fully replaced
previously used terms, such as “dosage forms”, in an attempt to emphasize the importance …

Background: The use of dry-powder inhalers (DPIs) to administer respiratory medicines is
increasing, and new DPIs are likely to be developed because of expiring patents. However …

First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
10768844&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

Background Dry powder inhalation (DPI) formulations have been widely studied for the
treatment of respiratory diseases, including COVID-19, which have become common and …